0000000001227744

AUTHOR

L. Bolondi

showing 5 related works from this author

Cost-effectiveness of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma

2009

Oncologymedicine.medical_specialtyCost effectivenessComputed tomographyInternal medicineBiopsymedicinebiopsynon-invasive diagnosiAASLDHepatologymedicine.diagnostic_testRecallbusiness.industryNon invasiveGastroenterologycomputed tomographymedicine.diseaseAmerican Association for the Study of the Liver Diseasegadolinium-magnetic resonance imagingsmall hepatocellular carcinomaCost-effectiveneHepatocellular carcinomaRadiologybusinesscontrast-enhanced ultrasoundContrast-enhanced ultrasoundDigestive and Liver Disease
researchProduct

Prophylaxis of venous thromboembolism in elderly patients with multimorbidity

2013

none 327 si Pharmacological thromboprophylaxis (TP) is known to reduce venous thromboembolism (VTE) in medical inpatients, but the criteria for risk-driven prescription, safety and impact on mortality are still debated. We analyze data on elderly patients with multimorbidities admitted in the year 2010 to the Italian internal medicine wards participating in the REPOSI registry to investigate the rate of TP during the hospital stay, and analyze the factors that are related to its prescription. Multivariate logistic regression, area under the ROC curve and CART analysis were performed to look for independent predictors of TP prescription. Association between TP and VTE, bleeding and death in …

MaleTVPSettore MED/09 - Medicina InternaComorbidityLogistic regressionFondaparinuxVENOUS THROMBOEMBOLISM; THROMBOPROPHYLAXIS; Medical PatientsMedical patients; Thromboprophylaxis; Venous thromboembolism; Aged; Aged 80 and over; Area Under Curve; Comorbidity; Female; Hospital Mortality; Hospitalization; Humans; Logistic Models; Male; Propensity Score; Venous Thromboembolism; Internal Medicine; Emergency MedicineThromboprophylaxis Venous thromboembolism Medical patients80 and overHospital MortalityAged 80 and overSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheMedical patients; Thromboprophylaxis; Venous thromboembolism; Aged; Aged; 80 and over; Area Under Curve; Comorbidity; Female; Hospital Mortality; Hospitalization; Humans; Logistic Models; Male; Propensity Score; Venous Thromboembolism; Internal Medicine; Emergency Medicineprophylaxis; venous thromboembolism; elderlyHospitalizationArea Under CurveEmergency MedicineFemaleprophylaxismedicine.drugVenous thromboembolismmedicine.medical_specialtyThromboprophylaxis; Venous thromboembolismmultimorbidityBarthel indexvenous thromboembolismMEDLINEMedical patients; Thromboprophylaxis; Venous thromboembolism; Aged; Aged 80 and over; Area Under Curve; Comorbidity; Female; Hospital Mortality; Hospitalization; Humans; Logistic Models; Male; Propensity Score; Venous Thromboembolism; Emergency Medicine; Internal Medicineelderly patientselderlyMedical patientsInternal medicineInternal MedicinemedicineHumansMedical prescriptionprophylaxis; venous thromboembolism; elderly patientsPropensity ScoreIntensive care medicineThromboprophylaxisAgedbusiness.industryprophylaxiMedical patients; Thromboprophylaxis; Venous thromboembolismprophylaxis; Venous thromboembolism; Elderly; multimorbidity; medical patients; thromboprophylaxismedicine.diseaseComorbidityLogistic ModelsPropensity score matchingbusinessVenous thromboembolism
researchProduct

Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study

2018

OBJECTIVES: Thrombocytopenia is a hallmark for patients with cirrhosis and it is perceived as a risk factor for bleeding events. However, the relationship between platelet count and bleeding is still unclear. METHODS: We investigated the relationship between platelet count and major or clinical relevant nonmajor bleedings during a follow-up of ∼4 years. RESULTS: A total of 280 cirrhotic patients with different degrees of liver disease (67% males; age 64±37 years; 47% Child–Pugh B and C) were followed up for a median of 1,129 (interquartile range: 800–1,498) days yielding 953.12 patient-year of observation. The annual rate of any significant bleeding was 5.45%/year (3.57%/year and 1.8…

Liver CirrhosisMaleSettore MED/09 - Medicina Interna030204 cardiovascular system & hematologyGastroenterologySeverity of Illness IndexcjirrhosisACTIVATION0302 clinical medicineRisk FactorsMedicinePlateletProspective StudiesProspective cohort studyRISKAged 80 and overmedicine.diagnostic_testPRO-LIVERPlatelet cirrhosis gastrointestinal bleedingPlateletGastroenterologyASSOCIATIONMiddle AgedPrognosisItaly030211 gastroenterology & hepatologyFemaleGastrointestinal HemorrhageHumanAdultPlateletsmedicine.medical_specialtyPrognosiLiver CirrhosiMEDLINECOAGULATIONgastrointestinal bleedingSocio-culturaleHemorrhageHepatology; GastroenterologyFollow-Up Studie03 medical and health sciencesText miningInternal medicineSeverity of illnessENDOTOXEMIAPro-Liver StudyHumansHEMOSTASISInternational Normalized RatioAgedProportional Hazards ModelsProthrombin timeCirrhosiHepatologyPlatelet Count Bleeding Liver Cirrhosisbusiness.industryProportional hazards modelPlatelet CountRisk FactorcirrhosisHepatologybleedingThrombocytopeniaProspective StudieTHROMBOSISPlatelets cjirrhosis bleeding PRO-LIVERProportional Hazards ModelProthrombin TimebusinessDECOMPENSATED CIRRHOSISFollow-Up Studies
researchProduct

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

2019

OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…

Liver CirrhosisPediatricsTime FactorsSettore MED/09 - Medicina InternaNational Health ProgramsERADICATIONOUTBREAKantiviral treatment anti HCV economic consequencesHepacivirusLIVER FIBROSISSeverity of Illness IndexHealth Services AccessibilityCOST-EFFECTIVENESSIndirect costs0302 clinical medicineEpidemiologyvirus infection030212 general & internal medicinehealth care economics and organizationscost effectiveness030503 health policy & servicesHealth PolicyHealth services researchhealthHepatitis CHepatitis CMarkov Chainschronic hepatitis C virus infection fibrosis progression cost effectiveness liver fibrosisItalyPharmacology; Health Policy; Public Health Environmental and Occupational HealthCohortSettore SECS-P/03 - Scienza delle FinanzeDisease ProgressionPublic Health0305 other medical scienceViral hepatitisAnti-HCV antiviral treatmentCHRONIC HEPATITIS-Cmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAVIRUS-INFECTIONAntiviral AgentsNO03 medical and health sciencesCost SavingsAntiviral Agents; Cost Savings; Disease Progression; Genotype; Health Policy; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Markov Chains; National Health Programs; Severity of Illness Index; Time FactorsmedicineMANAGEMENTHumanschronic hepatitis CINDUCED DISEASESMETAANALYSISPharmacologyHealth economicsbusiness.industryPublic healthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseFIBROSIS PROGRESSIONbusiness
researchProduct

SIUMB guidelines and recommendations for the correct use of ultrasound in the management of patients with focal liver disease

2019

The present document describes the SIUMB (Italian Society of Ultrasound in Medicine and Biology) guidelines for the use of ultrasound in the management of focal liver disease. The aim of the paper is to provide a clinical practice guideline for Italian physicians who are approaching the ultrasound study of a focal liver lesion. In particular, these guidelines provide simple indications, recommendations and general practice advices for the correct use of contrast-enhanced ultrasound (CEUS) in this scenario. They represent the SIUMB position of the ultrasound role in the diagnostic flow charts of the principal focal liver lesions, and are in agreement with other, previously published national…

medicine.medical_specialtySettore MED/09 - Medicina InternaHepatocellular carcinomaContrast enhanced ultrasoundCholangiocellular carcinoma; Contrast enhanced ultrasound; Focal nodular hyperplasia; Hemangioma; Hepatocellular carcinoma; MetastasisContrast MediaMetastasiCholangiocellular carcinoma030218 nuclear medicine & medical imagingMetastasis03 medical and health sciencesLiver disease0302 clinical medicineFocal nodular hyperplasiaInternal MedicineHumansMedicineRadiology Nuclear Medicine and imagingMedical physicsUltrasonographyUltrasound studybusiness.industryLiver NeoplasmsUltrasoundFocal nodular hyperplasiaGeneral MedicineGuidelinemedicine.diseaseClinical PracticeLiverLiver lesionOriginal Article030211 gastroenterology & hepatologyCholangiocellular carcinoma; Contrast enhanced ultrasound; Focal nodular hyperplasia; Hemangioma; Hepatocellular carcinoma; Metastasis; Contrast Media; Humans; Liver; Liver Neoplasms; UltrasonographybusinessHemangiomaContrast-enhanced ultrasound
researchProduct